Skin toxicities are the most common side effects associated with the epidermal growth factor
receptor inhibitor erlotinib, occurring in most patients receiving the drug. Clinical trials …

Introduction: All anticancer drugs can cause idiosyncratic liver injury. Therefore,
hepatoprotective agents assume particular importance to preserve liver function. Hepatic …

Background A previous randomized phase II study demonstrated that the addition of a c-Met
inhibitor tivantinib to an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor …

Objectives Drug-induced interstitial lung disease (ILD) is often associated with high
mortality; however it is difficult to predict and manage. we examined the clinical findings and …

Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …

Introduction The epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …

Background Pruritus has been anecdotally described in association with targeted cancer
therapies. The risk of pruritus has not been systematically ascertained. Objective A …

Since the approval of the first molecularly targeted tyrosine kinase inhibitor (TKI), imatinib, in
2001, TKIs have heralded a new era in the treatment of many cancers. Among their …

Aim: We planned a randomized, open-label trial to evaluate differences between pre-
emptive and reactive skin treatment for panitumumab (Pmab)-associated skin toxicities in …

Interstitial lung disease (ILD) occurrence and risk factors were investigated in the Japanese
non‐small‐cell lung cancer, post‐marketing, large‐scale surveillance study, POLARSTAR …